Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
NL0010391025
Wed, 09.08.2023
Pharming Group NV
First Berlin Equity Research has published a research update on Pharming
Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY
rating and increased the price target from EUR 1.50 to EUR 1.60.
Abstract:
Q2/23 saw the expected sequential recovery in Ruconest sales (+20.1%)
following temporary reimbursement problems in Q1/23. Ruc [ … ]
Tue, 18.07.2023
Pharming
First Berlin Equity Research has published a research update on Pharming
Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 1.80 to EUR 1.50.
Abstract:
Pharming's orphan drug, Joenja, for the treatment of the rare disease,
activated PI3K delta syndrome (APDS), was approved in t [ … ]
Tue, 18.07.2023
Pharming
First Berlin Equity Research has published a research update on Pharming
Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 1.80 to EUR 1.50.
Abstract:
Pharming's orphan drug, Joenja, for the treatment of the rare disease,
activated PI3K delta syndrome (APDS), was approved in t [ … ]
Tue, 04.08.2020
Pharming Group NV
First Berlin Equity Research hat ein Research Update zu Pharming Group NV
(ISIN: NL0010391025) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 2,10 auf EUR 1,80.
Zusammenfassung:
Die Q2/20-Ergebnisse von Pharming zeigten einen Umsatzrückgang von 8%
gegenüber dem Vorjahr auf [ … ]